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Abstract
Background: Delivery is the only definite cure for hypertensive disorders. Therefore,
cervical ripening and labor induction are important to achieve favorable outcomes.
Objective: This Randomized Control Trial (RCT) is aimed to compare the effects of
sublingual misoprostol and Foley catheter in cervical ripening and labor induction
among patients with preeclampsia or gestational hypertension.
Materials andMethods:A total number of 144 womenwith preeclampsia or gestational
hypertention with indication of pregnancy termination, who were referred to academic
hospitals of the University of Medical Sciences in Mashhad, Iran, between March 2015
and December 2016, were randomly divided into two groups. In group one (n = 72), 25
µg of misoprostol tablet was administrated sublingually every 4 hr up to six doses. In
group two (n = 72), a 16F Foley catheter was placed through the internal cervical os,
inflated with 60 cc of sterile saline.
Results: There were no significant differences between groups regarding the demo-
graphic characteristics, primary bishop score, and pregnancy termination indication.
The cervical ripening time (primary outcome) (8.2 vs 14.2 hr, p < 0.00), induction to
delivery interval (15.5 vs 19.9 hr, p < 0.00), and vaginal delivery before 24 hr (63.9%
vs 40%, p = 0.03) were significantly different between the two groups. There was
no significant difference between groups in view of oxytocin requirement (p = 0.12),
neonatal Apgar score (p = 0.84), or neonatal intensive care unit admission (p = 78).
Conclusion: This trial showed that the application of sublingual misoprostol, compared
to the Foley catheter, can reduce cervical ripening period and other parameters related
to the duration of vaginal delivery. This misoprostol regimen showed inconsiderable
maternal complications.
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1. Introduction
Hypertensive disorders complicate up to 10% of
all pregnancies. Even though many antihyperten-
sive agents are available to control preeclampsia,
the only definite cure is delivery (1). Therefore,
the induction of labor and cervical ripening are
momentous procedures in order to achieve favor-
able outcomes and to prevent morbidity and mor-
tality in both mother and the baby. Sublingual miso-
prostol and Foley catheter are two inexpensive
and frequently used cervical ripening and labor-
inducing methods.
During the last two decades, the rate of labor
induction has increased, in so far as up to 20-
30% of all labors are induced for different reasons
(2). Despite the fact that these two methods are
used frequently, their relative risks and benefits are
unknown, and contradictory results are reported
in different trials. Since the conditions of a pre-
eclamptic patient are unstable, an ideal ripening
method results in a relatively shorter ripening dura-
tion. Moreover, leading to a fast vaginal delivery
without increasing risk to the fetus or the rate of
urgent cesarean delivery seems to be a necessary
feature.
This study is aimed to evaluate and compare the
effect of sublingual misoprostol and Foley catheter
in cervical ripening among pregnant women with
preeclampsia or gestational hypertension.
2. Materials and Methods
This randomized clinical trial was conducted
among 144 women with preeclampsia or gesta-
tional hypertention with indication of pregnancy
termination in Ghaem and Imam Reza Hospitals,
Mashhad University of Medical Sciences, Iran,
betweenMarch 2015 and December 2016. Patients
were randomly allocated to sublingual misoprostol
(n = 72) or Foley catheter group (n = 72) using
the sealed envelope system. During the study, 18
patients in the misoprostol group and 1 patient in
Foley catheter group were excluded from the trial
(Figure 1).
The inclusion criteria were as follows:
preeclampsia or gestational hypertension with
indication of pregnancy termination, singleton
pregnancies, gestational age of > 26 wk, cephalic
presentation, unfavorable cervix (bishop score
< 6), the absence of active labor, normal fetal
heart rate (FHR), and the absence of previous
cesarean delivery or uterine scar or macrosomia
or Placenta Previa. We have excluded individuals
with hypersensitivity to prostaglandins and those
who could not continue the study.
In the misoprostol group, 25 µg misoprostol (1/4
of a 100 µg misoprostol tablet; Cytotec, Searl &
Co, England) was administered sublingually every
4 hr up to a maximum of six doses, if needed. In
case of a non-reassuring FHR or in the presence
of three or more contractions in 10 min, a subse-
quent misoprostol dose was withheld. Moreover, if
augmentation was required, a low-dose Oxytocin
regimen infusion was used (2 mlU/min initially,
drops were increased 2 mlU/min each 20 min if
needed).
In Foley Catheter group, a 16 French size sil-
icone Foley catheter was placed in the cervix
through the internal orifice of the cervix (inter-
nal os) using a vaginal speculum under asep-
tic condition, then it was inflated with 60 cc
of sterile saline. The external end of the Foley
catheter was taped to the thigh without traction.
The catheter was expelled spontaneously or by
the physician if the bishop score remained less
than 6 after 24 hr of insertion. After catheter
expulsion, a low-dose Oxytocin regimen was
used if contractions were less than 4 in 10
min.
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During the intervention, FHR was monitored
continuously. A gynecology resident examined
patients every 2 hr. If uterine tachysystole (6 or
more contractions in 10 min) occurred, the patient
was positioned laterally; a 500 cc Ringer lactate
infusion and a 10 Lit/m oxygen therapy were
applied.
In both groups, cesarean section was performed
in case of cervical dilatation arrest (if no cervical
dilatation happened during active phase in 2 hr),
fetal descent arrest (if no fetal descent happened
during the second stage of delivery in 1 hr), or fetal
distress (in case of late, prolonged, or significant
variable decelerations in the cardiotocography).
All patients were followed up until 24 hr after
the delivery in order to check any possible side
effect.
Our primary outcome was the cervical
ripening duration that defined as the period
of the time between the commencement of the
intervention and the first vaginal exam in which
the patient’s bishop score was more than 6.
Secondary outcomes were oxytocin requirement,
cesarean delivery, induction to delivery interval,
the vaginal delivery rate in 24 hr, maternal side
effects (post-delivery hemorrhage, fever within
24 hr after delivery, diarrhea, and tachysystole),
neonatal Apgar score, and neonatal intensive care
unit (NICU) admission.
According to the data from the trial by Vahid
and colleagues, our trial sample size with 95%
confidence interval and 80% power was calculated
in at least 36 subjects in each group (3). We
doubled it to 72 in order to increase accuracy.
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Figure 1. Consort flow diagramfor participants involved in the trial.
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2.1. Ethical consideration
This trial was approved by the ethics
committee of the Mashhad University of
Medical Sciences (no: IR.MUMS.REC.1394.498)
and by the Iranian Registry of Clinical Trials
(IRCT2017010731725N1). All participants provided
oral and written informed consent. Due to the
nature of the interventions, blinding was not
possible.
2.2. Statistical analysis
Statistical analyses were done by SPSS soft-
ware; (Statistical Package for the Social Science,
version 16.0, SPSS Inc., Chicago, IL, USA). The
t-test (for independent and dependent samples)
was used for the comparison of quantitative
data. Nonparametric methods were used in cases
where data were not normally distributed. The chi-
squared test was used to compare the studied
variables. We considered p < 0.05 as signifi-
cant.
3. Results
125 women with the mean age of 26.1 ± 4.5
yr, ranged between 17-36 yr old were enrolled.
Misoprostol and Foley catheter groups were sim-
ilar in the view of demographic characteristics
including age, gestational age, parity, and pri-
mary Bishop score (p > 0.05; Table I). The
majority of patients in both groups were nulli-
parous and had Bishop score less than three at
recruitment. The mean administrated dose in the
misoprostol group was 2.3 ± 0.7 and most of the
patients received 2–3 doses of misoprostol (n: 45,
83.3%).
The cervical ripening time (primary outcome)
and induction to vaginal delivery interval were
significantly shorter in the misoprostol group com-
pared to the Foley catheter group (p < 0.001;
Table II). Vaginal birth within 24 hr was signif-
icantly more common in women in the miso-
prostol group than in the Foley catheter group
(63.9% vs 40.0%, p = 0.03). Oxytocin augmentation
requirement was higher in the Foley catheter
group; however, this difference did not reach
statistical significance (p = 0.12). Among cases
who had to undergo cesarean section, there
was no statistical difference in the indications
for cesarean section between two groups (p =
0.45).
Generally, maternal complications were more
common in the Foley catheter group than
the misoprostol group. One woman (1.4%) in
the Foley group had postpartum bleeding
due to atonia; three women in the Foley
catheter group (4.2%) and one woman in the
misoprostol group (1.8%) had fever within 24
hours after the delivery. One woman (1.8%)
in the misoprostol group experienced uterine
tachysystole.
There was no significant difference between
groups in view of neonatal fifthminute Apgar score,
the rate of NICU admission, and NICU admission
due to prematurity (p = 0.84, p = 0.78 p = 0.67,
respectively).
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Table I. Baseline clinical characteristics of misoprostol and Foley catheter group
Variable Misoprostol group (n: 54) Foley catheter group (n:
71)
Total (n: 125) P-value
Maternal age (yr)* 26.1 ± 4.3 26.1 ± 4.5 26.1 ± 4.4 0.97
Gestational age (wk)* 35.1 ± 2.4 34.7 ± 2.5 34.9 ± 2.5 0.89
Primary Bishop score:**
0–2 34 (63.0) 48 (67.6) 82 (65.6)
3–6 20 (37.0) 23 (32.4) 43 (34.3)
0.58
Type of parity:**
Nulliparous 31 (57.4) 49 (69.0) 80 (64.0)
Multiparous 23 (42.6) 22 (31.0) 45 (36.0)
0.18
Pregnancy termination Indication:**
Gestational hypertension 13 (24.0) 18 (25.0) 31 (24.8)
Preeclampsia 37 (68.5) 49 (69) 86 (68.8)
Eclampsia 4 (7.4) 4 (5.6) 8 (6.4)
0.91
*Data presented as mean ± SD
**Data presented as n (%)
The t-test was used to analyze continuous data, and Chi-Square and Mann–Whitney test were used for nonparametric data
analysis
Table II. Comparison of study outcomes between Misoprostol and Foley catheter groups
Variable Misoprostol group (n:54) Foley catheter group (n:71) P-value
Cervical ripening time (hr)* 8.2 ± 3.8 14.2 ± 4.2 < 0.001
Induction to vaginal delivery interval (min)* 15.6 ± 7.5 20.0 ± 7.0 < 0.001
Vaginal birth within 24 hr** 23 (63.9) 18 (40.0) 0.03
Oxytocin requirement** 17 (31.5) 32 (45.5) 0.12
Vaginal delivery** 36 (66.7) 45 (63.4) 0.70
Cesarean section due to fetal distress** 12 (66.7) 20 (76.9) 0.45
Fifth minute apgar over 8** 41 (82) 56 (80) 0.84
NICU admission** 14 (25.9) 20 (28.2) 0.78
NICU admission due to prematurity** 11 (78.6) 16 (84.2) 0.67
*Data presented as mean ± SD
**Data presented as n (%)
The t-test was used to analyze continuous data and Chi-Square test was used for nonparametric data analysis
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4. Discussion
The results of this study showed that sublingual
misoprostol comparing to Foley catheter signifi-
cantly reduces cervical ripening time. In two studies
by Adeniji and colleagues and a study by Aduloju
and co-workers, the same result was reported (4-6).
In this trial, the mean induction-to-delivery inter-
val was significantly shorter in the misoprostol
group than in the Foley catheter group. This was
similarly reported in some previous studies (7-11).
In addition, a nonsignificant shorter induction-to-
delivery interval in misoprostol group was reported
by Barrilleaux et al. and Fox and co-workers (12, 13).
On the other side, Prager and colleagues reported
a significantly shorter induction-to-delivery interval
in the catheter group compared to the misoprostol
group, which is in contrary to our findings (14). In
Prager study, the catheter was under traction and
misoprostol was administered vaginally; however,
in our study, we did not put catheter under trac-
tion and we administered misoprostol sublingually.
Sublingual administration of misoprostol can lead
to a quicker onset of action and a higher bioavail-
ability compared to vaginal rout.
In this research, sublingual misoprostol led to a
higher vaginal delivery rate within 24 hours. Chen
and coworkers have reported the same result in
their meta-analysis (15). Furthermore, some other
studies reported a higher vaginal delivery rate
within 12 hours in the misoprostol group compared
to the Foley catheter group (10, 16). In this trial,
an insignificant fewer number of women in the
misoprostol group required oxytocin augmenta-
tion rather than those in Foley catheter group.
Barrilleaux and colleagues also declare the same
result in their trial (12). However, some researchers
reported a significantly higher oxytocin require-
ment in Foley catheter group (6, 16-18).
This study demonstrated no significant differ-
ence in the mode of delivery between the two
groups, which was also reported in similar previ-
ous studies (5, 6, 9, 19). Contrary to our study,
Vahid and colleagues and Noor et al. reported
a significantly higher rate of vaginal delivery
in the misoprostol group rather than the Foley
catheter group (3, 11). Vaginal administration of
misoprostol and term gestational age among their
patients can be an explanation for this contra-
diction. Since the success rate of labor induction
can be higher in multiparous women rather than
nulliparous ones, multiparous status in majority of
Vahid‘s women might be another reason for this
incompatibility. Moreover, our study was limited
to subjects with preeclampsia and gestational
hypertension that can be a cesarean indication by
itself and may lead to a higher rate of cesarean
delivery compared to non-preeclamptic patients
(20).
Our trial showed few maternal complications
in each group. Three cases in Foley catheter
group experienced fever within 24 hr after delivery
that can be related to chorioamnionitis. In the
catheter group, 60% of the patients experienced
a prolonged induction-to-delivery interval (over 24
hr), which can be a risk factor for chorioamnionitis.
On the other hand, only one case of fever within 24
hr after the delivery was reported in themisoprostol
group that might have happened as a misoprostol
side effect.
Among cases that underwent cesarean sec-
tion in both groups, most cesarean sections
were performed due to fetal distress; however,
cesarean indications were not significantly dif-
ferent between the two groups. Therefore, we
cannot relate fetal distress to any of these labor-
inducing methods. Moreover, both groups were
similar in the view of the first- and fifth-minute
neonatal Apgar score and rate of NICU admis-
sion or NICU admission indication. Some other
studies reported the same results (3, 6, 17,
18).
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Sublingual administration of misoprostol in cer-
vical ripening and labor induction is the main
strength of this study and only a few trials have
studied this method before, especially on high-
risk patients. In a recent study, a mean ripening
time was obtained in both misoprostol and Foley
catheter groups that can practically be useful; this
variable has not been defined exactly in former
similar studies. Since no 25 µg misoprostol tablet
exists, we manually divided each 100 µg tablet
into four equal pieces using a pill cutter that
could influence the exact dosage of misoprostol.
However, it does not disprove the results of the
current trial.
In view of the fact that few complications for
sublingual misoprostol were reported in this trial,
it seems reasonable to conduct studies in future in
order to compare sublingual misoprostol to buccal
or other new routs of misoprostol administration.
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